Literature DB >> 15759

Haemodynamic long-term effects of beta-receptor-blocking agents in hypertension: a comparison between alprenolol, atenolol, metoprolol and timolol.

P Lund-Johansen, O J Ohm.   

Abstract

1. Oxygen consumption and central haemodynamics were recorded at rest and during exercise in fifty-one men with essential hypertension (W.H.O. stage I) and repeated after 1 year on a single drug: alprenolol (n equals 10), atenolol (13) metoprolol (12) and timolol (16). 2. Mean arterial pressure was significantly reduced in all groups at rest (11-18%) and during exercise (5-11%). Heart rate was significantly reduced in all groups (20-28%) at rest and (17-26%) during exercise. Owing to increase in supine resting and exercise stroke volume in the alprenolol and atenolol group, cardiac index decreased less than heart rate---in contrast to the timolol group where cardiac index was decreased 26-32%. The calculated post-treatment total peripheral resistance was significantly increased at rest and during exercise in the timolol group. In the other groups the total peripheral resistance was significantly increased at rest when sitting, but not at rest when supine and during exercise. 3. It is concluded that the major haemodynamic changes induced in subjects with moderate and mild essential hypertension by these different beta-receptor blockers are the same, but that minor differences exist with respect to effect upon stroke volume and total peripheral resistance.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 15759     DOI: 10.1042/cs051481s

Source DB:  PubMed          Journal:  Clin Sci Mol Med Suppl        ISSN: 0144-4107


  11 in total

1.  Haemodynamic adaptation at rest and during exercise to long-term antihypertensive treatment with combined alpha- and beta-adrenoreceptor blockade by labetalol.

Authors:  G Koch
Journal:  Br Heart J       Date:  1979-02

Review 2.  Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

3.  Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89,406 in healthy volunteers.

Authors:  T L Svendsen; O Hartling; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

4.  Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin.

Authors:  P Lund-Johansen
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

5.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 6.  Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-06       Impact factor: 9.546

7.  Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.

Authors:  D Maclean; E T Mitchell; R R Coulson; T J Fitzsimons; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

8.  Haemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients.

Authors:  A Svensson; T Gudbrandsson; R Sivertsson; L Hansson
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

9.  An assessment of lacidipine and atenolol in mild to moderate hypertension.

Authors:  D Lyons; G Fowler; J Webster; S T Hall; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

10.  Comparison of the cardiovascular effects of nifedipine and nicardipine in the presence of atenolol.

Authors:  S H Thomas
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.